Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-κB activity via the Notch-1 pathway

International Journal of Molecular Medicine

Volumn 30, Issue 2, 2012, Pages 337-343

  Pan, Hong ^a   Zhou, Wenbin ^a   He, Wei ^a   Liu, Xiaoan ^a   Ding, Qiang ^a   Ling, Lijun ^a   Zha, Xiaoming ^a   Wang, Shui ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Genistein; Notch 1 signaling pathway; Nuclear factor B; Triple negative breast cancer

Indexed keywords

CYCLIN B1; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOTCH1 RECEPTOR; PROTEIN BCL 2; PROTEIN BCL XL; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL NUCLEUS; CELL PROLIFERATION; CHRONOTHERAPY; DOSE RESPONSE; DOWN REGULATION; DRUG EXPOSURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING;

APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; FEMALE; GENISTEIN; HUMANS; NF-KAPPA B; PROTEIN KINASE INHIBITORS; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION;

EID: 84863553441     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.990     Document Type: Article

References (37)

1. Jemal A, Seige R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Smith RA, Cokkinides V, Brooks D, Saslow D, Shah M and Brawley OW: Cancer screening in the United States, 2011: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 61: 8-30, 2011.
3. Lara-Medina F, Perez-Sanchez V, Saavedra-Perez D, et al: Triple negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer 117: 3658-3669, 2011.
4. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502, 2006.
5. Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434, 2007.
6. Haffty BG, Yang Q, Reiss M, et al: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24: 5652-5657, 2006.
7. Rakha EA, EI-Sayed ME, Green AR, Lee AH, Robertson JF and Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer 109: 25-32, 2007.
8. Tischkowitz M, Brunet JS, Begin LR, et al: Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7: 134, 2007.
9. Wu AH, Yu MC, Tseng CC and Pike MC: Epidemiology of soy exposures and breast cancer risk. Br J Cancer 98: 9-14, 2008.
10. Wu AH, Koh WP, Wang R, Lee HP and Yu MC: Soy intake and breast cancer risk in Singapore Chinese Health Study. Br J Cancer 99: 196-200, 2008.
11. Lee SA, Shu XO, Li H, et al: Adolescent and adult soy food intake and breast cancer risk: results from the Shanghai Women's Health Study. Am J Clin Nutr 89: 1920-1926, 2009.
12. Shu XO, Zheng Y, Cai H, Gu K, Chen Z, Zheng W and Lu W: Soy food intake and breast cancer survival. JAMA 302: 2437-2443, 2009.
13. Dong JY and Qin LQ: Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. Breast Cancer Res Treat 125: 315-323, 2011.
14. Li Z, Li J, Mo B, et al: Genistein induces cell apoptosis in MDA-MB-231 breast cancer cells via the mitogen-activated protein kinase pathway. Toxicol in Vitro 22: 1749-1753, 2008.
15. Li Z, Li J, Mo B, et al: Genistein induces G2/M cell cycle arrest via stable activation of ERK1/2 pathway in MDA-MB-231 breast cancer cells. Cell Biol Toxicol 24: 401-409, 2008.
16. Speiser J, Foreman K, Drinka E, et al: Notch-1 and Notch-4 biomarker expression in triple-negative breast cancer. Int J Surg Pathol: Nov 13, 2011 (Epub ahead of print).
17. Shih IeM and Wang TL: Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 67: 1879-1882, 2007.
18. Oswald F, Liptay S, Adler G and Schmid RM: NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa. Mol Cell Biol 18: 2077-2088, 1998.
19. Stylianou S, Clarke RB and Brennan K: Aberrant activation of notch signaling in human breast cancer. Cancer Res 66: 1517-1525, 2006.
20. Gray GE, Mann RS, Mitsiadis E, et al: Human ligands of the Notch receptor. Am J Pathol 154: 785-794, 1999.
21. Gidzinska B: Notch1 receptor: structure and role during T-cell development. Postepy Hig Med Dosw 57: 369-376, 2003 (In Polish).
22. Reedijk M, Odorcic S, Chang L, et al: High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65: 8530-8537, 2005.
23. Reedijk M, Pinnaduwage D, Dickson BC, et al: JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res Treat 111: 439-448, 2008.
24. Dickson BC, Mulligan AM, Zhang H, Lockwood G, O'Malley FP, Egan SE and Reedijk M: High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 20: 685-693, 2007.
25. Miele L: Rational targeting of Notch signaling in breast cancer. Expert Rev Anticancer Ther 8: 1197-1202, 2008.
26. Rizzo P, Miao H, D'Souza G, et al: Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 68: 5226-5235, 2008.
27. Cogswell PC, Guttridge DC, Funkhouser WK and Baldwin AS Jr: Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 19: 1123-1131, 2000.
28. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr and Sledge GW Jr: Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17: 3629-3639, 1997.
29. Sovak MA, Bellas RE, Kim DW, et al: Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100: 2952-2960, 1997.
30. Nakshatri H and Goulet RJ Jr: NF-kappaB and breast cancer. Curr Probl Cancer 26: 282-309, 2002.
31. Chen LF, Fischle W, Verdin E and Greene WC: Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293: 1653-1657, 2001.
32. Kawamoto H, Koizumi H and Uchikoshi T: Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses. Am J Pathol 150: 15-23, 1997.
33. Yuan J, Yan R, Krämer A, Eckerdt F, Roller M, Kaufmann M and Strebhardt K: Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene 23: 5843-5852, 2004.
34. Viatour P, Bentires-Alj M, Chariot A, Deregowski V, de Leval L, Merville MP and Bours V: NF-kappa B2/p100 induces Bcl-2 expression. Leukemia 17: 1349-1356, 2003.
35. Luna-Moré S, Casquero S, Pérez-Mellado A, Rius F, Weill B and Gornemann I: Importance of estrogen receptors for the behavior of invasive micropapillary carcinoma of the breast. Review of 68 cases with follow-up of 54. Pathol Res Pract 196: 35-39, 2000.
36. Wang S, Yang D and Lippman ME: Targeting Bcl-2 and Bcl-xL with nonpeptidic small-molecule antagonists. Semin Oncol 30: 133-142, 2003.
37. Liu R, Page C, Beidler DR, Wicha MS and Núñez G: Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model. Am J Pathol 155: 1861-1867, 1999.